Alacrita

Dr Susan Foden holds a number of non-executive directorships with both public and private companies and public funding bodies in the biotech and healthcare field, including Vectura plc, Source Bioscience plc, Cell Centric Ltd, Cizzle Ltd, Rainbow Seed Fund, Cascade Ltd, Oxford Ancestors Ltd, and was a Trustee of The Institute of Cancer Research.

She is a member of the advisory boards of Elara GmbH, the University of Manchester Premier Fund and the University of Leuven intiative in drug discovery, CD3.

Prior to this Susan held positions in venture capital and UK biotech companies. From 2000 to 2003 she was an Investor Director with the London-based venture capital firm Merlin Biosciences Ltd, and was Chief Executive Officer of the technology transfer company Cancer Research Campaign Technology Ltd from 1987 to 2000.

She studied biochemistry at the University of Oxford from where she obtained an MA and a DPhil.